Exelixis (NASDAQ:EXEL) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's (NASDAQOTH:RHHBY) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival.
Of course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important. In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
